Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $58 | $63 | $66 |
| Gross Profit | -$2 | -$58 | -$63 | -$66 |
| % Margin | – | – | – | – |
| R&D Expenses | $218 | $243 | $255 | $345 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,045 | $594 | $908 | $1,781 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$650 | -$50 |
| Operating Expenses | $1,262 | $837 | $513 | $2,076 |
| Operating Income | -$1,262 | -$837 | -$513 | -$2,076 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $611 | $1,616 | -$40 | -$20 |
| Pre-Tax Income | -$652 | $779 | -$553 | -$2,097 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$518 | $867 | -$435 | -$1,894 |
| % Margin | – | – | – | – |
| EPS | -0.024 | 0.06 | -0.03 | -0.13 |
| % Growth | -140% | 298% | 76.8% | – |
| EPS Diluted | -0.024 | 0.06 | -0.03 | -0.13 |
| Weighted Avg Shares Out | 24,116 | 14,486 | 14,415 | 14,290 |
| Weighted Avg Shares Out Dil | 24,116 | 14,486 | 14,415 | 14,290 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $57 | $44 | $40 | $20 |
| Depreciation & Amortization | $2 | $58 | $63 | $66 |
| EBITDA | -$1,260 | -$779 | -$450 | -$2,010 |
| % Margin | – | – | – | – |